Download the PDF to hear from our new Chairman and CEO, Daniel O'Day.
End the HIV
Cure for HIV
The Fight Starts Here
Gilead has been a leading innovator for 30 years, working to help people treat and prevent HIV and to drive research for a cure. Despite tremendous advances in the field, HIV is still an epidemic with an unequally heavy impact among the most marginalized populations. Through our scientific efforts, community support programs and partnerships with leading health organizations, we’re continuing to break down barriers and help strengthen public health systems — efforts critical to ending the HIV epidemic once and for all.
Treatment Can Help People Live Longer and Healthier
People living with HIV who are on treatment and engaged in care can enjoy healthier lives — living longer than ever before thanks in part to our medicines.
Prevention Starts with Education
Comprehensive HIV prevention plays a critical role in ending the epidemic and should include broad community education and biomedical interventions such as PrEP, PEP and TasP.
Our Sights Are Set On a Cure
Finding a cure for HIV presents a formidable challenge. Despite this, we’re relentless in our pursuit because we believe that it may one day be within reach.
An estimated 11.5 million people living with HIV in resource-limited countries receive antiretroviral therapies provided by Gilead or one of our manufacturing partners.
Spread Facts, Not Fear
Stigma thrives on ignorance. So when it comes to fighting HIV, it’s about more than just developing medicines: We need to educate our communities to improve understanding. It’s all about having and normalizing the conversation. The Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative™ was established to do just that, helping community-based organizations reduce HIV-related health disparities, build awareness, advance education and reduce stigma in the Southern United States.
Together, We Can Make a Real Impact
Over the 15 years we've worked in resource-limited countries, we've learned there's no one-size-fits-all approach to treating and preventing HIV. That's why we partner with nongovernmental organizations, governments and academic institutions to enhance our collective impact. Collaborative research not only leads to more innovative approaches, it also helps countries map their disease burdens. Together, we're able to raise awareness, reduce stigma and deliver frontline services and care around the world.
in the Power
Cell Therapy Can Change the Game
Chimeric antigen receptor T cell therapy, better known as CAR T, re-engineers a patient’s white blood cells to detect and kill cancer cells. It’s an innovative approach that transforms a patient’s immune system into their own cancer-fighting therapy. We believe it’s a key milestone in the journey to cure cancer, and we’re eager to help advance the field to benefit patients now and in the future.
Ushering in Our Next Phase
of Cancer Therapies
Cell therapy is transforming cancer care with what is potentially the biggest breakthrough since
the introduction of combination chemotherapy more than 60 years ago. And it’s advancing
quickly, indicating a potential path toward a cure for patients affected by cancer.
Kite Pharma files first Investigational New Drug (IND) application
Kite wins “Clinical Trial Result of the Year” for CAR T trial in patients with aggressive non-Hodgkin lymphoma (NHL)
Gilead Sciences completes acquisition of Kite Pharma and Yescarta® (axicabtagene ciloleucel) becomes the first FDA-approved CAR T therapy for large B-cell lymphoma
Kite, a Gilead Company, becomes first to initiate a global randomized trial for CAR T therapy as a second-line treatment option
Gilead plans to continue expanding access to our CAR T therapy throughout the U.S. and Europe
Why We’re Investing in Cell Therapy
Kite’s development of its CAR T therapy, which is individually manufactured for each patient, has made a significant difference for treating large B-cell lymphoma. Beyond this, Gilead and Kite are seeking to advance our work by ultimately developing therapies for other hematological cancers and for solid tumors.
in the Power
Diversity Drives Our Innovation
Our diversity defines us. It fuels our work, inspiring us to innovate, collaborate and ultimately better serve patients around the world. We embrace diversity in a number of ways at Gilead. That's where our Employee Resource Groups (ERGs) come in: They help create a sense of purpose and amplify diverse voices throughout the company. Built and led by employees, our ERGs provide mentorship opportunities, boost our collective social awareness and enhance our community connections.
Gilead Asian Interest Network (GAIN)
GAIN unites Asian employees and their allies to deepen cultural understanding across the company.
Gilead Leadership Organization of Black Employees (GLOBE)
GLOBE works to cultivate leadership among people of African descent, advancing opportunities for all people to be valued.
Women at Gilead
Our global network of Women at Gilead boosts how we recruit, develop and support our female employees — so they can thrive now and into the future.
The LGBTQ+ Alliance
The LGBTQ+ Alliance is all about keeping Gilead a place where gender diversity is celebrated, community is prioritized and all people feel empowered.
Gileados members embrace and espouse an appreciation for the multifaceted Latino culture at Gilead, with the goal of enhancing the recruitment and retention of diverse talent.
Gilead Veterans Engagement Team (GVET)
GVET plays an important role in how we recognize, appreciate and support veterans, active duty military and their families.
We Stand Up for Our People
The diseases we treat — such as HIV and hepatitis — still disproportionately affect people who identify as LBGTQ+, and we fiercely support that community. We advocate for transgender rights. We march in Pride parades. We host honest conversations about what it means to make sure everyone feels truly included. We invest in programs that fight stigma. We stand with our LGBTQ+ employees and take pride in the difference they make at Gilead and in our communities.